US 7,304,174 · Application 10/830,480 · Granted Dec 4, 2007
US 7,304,174
Casr antagonist
Estimated expiration
September 24, 2025
Expired 379 days ago
Earliest effective filing
Apr 23, 2004
+ 20 years
Apr 23, 2024
PTA +519d
Sep 24, 2025
No TD
—
Final
Sep 24, 2025
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- April 23, 2004
- Earliest effective filing
- April 23, 2004
- Issue date
- December 4, 2007
- PTA
- +519 days
- Base expiry (before PTA)
- April 23, 2024
April 23, 2004 + 20 years = April 23, 2024 + 519 PTA days = September 24, 2025
Continuity chain
No continuity chain; the patent’s own filing date was used.
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 10/830,480 · US 7,304,174
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 7,304,174: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US7304174Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.